Insider Selling: Cerus Co. (NASDAQ:CERS) CFO Sells 31,148 Shares of Stock

Cerus Co. (NASDAQ:CERS - Get Free Report) CFO Kevin Dennis Green sold 31,148 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $46,722.00. Following the completion of the sale, the chief financial officer now owns 935,754 shares in the company, valued at $1,403,631. The trade was a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kevin Dennis Green also recently made the following trade(s):

• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Stock Performance

Shares of NASDAQ:CERS traded down $0.03 on Wednesday, hitting $1.47. The company's stock had a trading volume of 637,507 shares, compared to its average volume of 1,302,988. The company has a market capitalization of $272.18 million, a price-to-earnings ratio of -13.41 and a beta of 1.56. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.54. The stock's 50-day moving average is $1.73 and its two-hundred day moving average is $1.78.

Cerus (NASDAQ:CERS - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million during the quarter, compared to analyst estimates of $50.81 million. On average, equities research analysts forecast that Cerus Co. will post -0.08 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CERS. Bank of New York Mellon Corp boosted its stake in Cerus by 1.2% during the 4th quarter. Bank of New York Mellon Corp now owns 485,797 shares of the biotechnology company's stock valued at $748,000 after purchasing an additional 5,721 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Cerus by 3.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 209,246 shares of the biotechnology company's stock valued at $322,000 after buying an additional 6,633 shares in the last quarter. Invesco Ltd. grew its holdings in Cerus by 8.3% during the fourth quarter. Invesco Ltd. now owns 86,787 shares of the biotechnology company's stock worth $134,000 after acquiring an additional 6,665 shares during the period. Creative Planning raised its position in Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 8,411 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Cerus by 3.7% in the fourth quarter. Rhumbline Advisers now owns 238,795 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 8,458 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.